Market Signal Briefing

New York, New York--(Newsfile Corp. - March 2, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Boston Scientific Corporation ("Boston Scientific Corporation") (NYSE: BSX) concerning potential violations of the federal securities laws.

On February 4, 2026, Boston Scientific reported fourth-quarter 2025 results. While the company exceeded analyst expectations for earnings per share and total revenue, its electrophysiology segment reported sales of $890 million, approximately $43 million below the $933 million consensus estimate. The EP segment has been positioned as the primary growth engine for the company, driven by its FARAPULSE pulsed field ablation system and related cardiac rhythm management products.

The electrophysiology market represents one of the fastest-growing areas in cardiovascular medicine, with pulsed field ablation technology emerging as a potential replacement for traditional thermal ablation procedures. Boston Scientific entered this market through its acquisition of Farapulse in 2021 and has invested heavily in expanding manufacturing capacity and physician training programs. The company projected that global PFA penetration would reach 50% by the end of 2025 and grow to approximately 80% by 2028.

During the Q3 2025 earnings call on October 22, 2025, CEO Mike Mahoney stated the company was "guiding to organic growth of 11% to 13% for fourth quarter '25" and expressed that the company was "incredibly proud of our EP performance, with third quarter sales growing 63%." The company had emphasized EP growth rates of 94% in Q2 2025 and 63% in Q3 2025.

During the first Q&A exchange following the Q4 2025 earnings release, analysts noted the street was expecting approximately 25% EP growth for the quarter. Management's discussion indicated confidence in only approximately 15% growth going forward, representing a significant gap between market expectations and the company's internal outlook.

Following the earnings release, BSX shares fell 17.5% with the stock reaching a 52-week low of $75.50.

If you suffered a loss on your Boston Scientific Corporation securities and would like to explore a potential recovery under the federal securities laws, Learn More About the Investigation or contact Joseph E. Levi, Esq. via email at [email protected] or call (212)363-7500 to speak to our team of experienced shareholder advocates.

WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285899

Source: Levi & Korsinsky, LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with FENhance 2 results showing 59% reduction -

- FENhance 1 is the final study readout of the fenebrutinib pivotal clinical development program in MS, following positive results for FENhance 2 in RMS and for FENtrepid in primary progressive multiple sclerosis (PPMS) -

- Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology -

- Totality of data from all three Phase III fenebrutinib studies will be submitted to regulatory authorities -

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the pivotal Phase III study (FENhance 1) of fenebrutinib in RMS met its primary endpoint, showing clinically meaningful and statistically significant results. The study demonstrated that fenebrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor, markedly reduced the annualized relapse rate (ARR) by 51% compared to teriflunomide over a period of at least 96 weeks of treatment, consistent with FENhance 2 results showing a 59% reduction in ARR. Together, these results equate to approximately one relapse every 17 years. Secondary endpoints in both RMS studies show statistically significant and clinically meaningful reductions in brain lesions. Additionally, all progression endpoints show favorable trends for fenebrutinib.

Full data from the FENhance 1 and 2 studies will be shared at the American Academy of Neurology (AAN) Annual Meeting 2026 and submitted to regulatory authorities together with data from the FENtrepid study.

“These pivotal results, together with the earlier data, provide convincing evidence that fenebrutinib can become the first high-efficacy oral treatment for RMS and PPMS,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “Building on a decade of transforming MS treatment, we are committed to advancing innovation to one day allow people with MS to live a life without disability.”

The positive FENhance 1 study follows positive results for FENhance 2 in RMS and for FENtrepid in PPMS, which were both announced in November. The collective positive results across all three pivotal studies demonstrate that fenebrutinib consistently shows a profound benefit on relapsing and progressive disease biology.

In both RMS studies, liver transaminase elevations were comparable with teriflunomide. In the FENhance 1 study, there was one Hy’s Law case in the fenebrutinib arm and one in the teriflunomide arm. Both cases were asymptomatic and resolved after study drug discontinuation. There were no additional Hy's Law cases across all of the fenebrutinib clinical development program in MS or in other autoimmune diseases.

In the FENhance 1 and 2 studies in RMS, 1 fatal case was reported in the teriflunomide arm and 8 fatal cases with various causes and at different points in treatment in the fenebrutinib arms. Further analyses are ongoing to better understand these findings.

Fenebrutinib targets cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression. Fenebrutinib, a non-covalent BTK inhibitor, is designed to have high potency, selectivity and reversibility. This design allows it to act throughout the body, and also to cross the blood-brain barrier into the central nervous system (CNS) targeting chronic inflammation.

About the FENhance 1 and 2 studies

FENhance 1 and 2 are two Phase III multicenter, randomized, double-blind, double-dummy, parallel-group studies to evaluate the efficacy and safety of investigational fenebrutinib compared with teriflunomide in a total of 1,497 adult patients with RMS. Eligible participants were randomized 1:1 to receive treatment with either oral fenebrutinib twice a day (and placebo matched to oral teriflunomide once a day) or oral teriflunomide once a day (and placebo matched to oral fenebrutinib twice a day) for at least 96 weeks.

The primary endpoint is annualized relapse rate (ARR). Secondary endpoints include total number of T1-gadolinium-enhancing MRI lesions, total number of new and/or enlarging T2-weighted MRI lesions, time to onset of 12-week composite confirmed disability progression (cCDP12) and 24-week cCDP (cCDP24). cCDP incorporates three measures of disability – total functional disability measured by confirmed disability progression (CDP) based on the Expanded Disability Status Scale (EDSS), walking speed measured by the timed 25-foot walk (T25FW) and upper limb function measured by the nine-hole peg test (9HPT).

Following the double-blind treatment period, patients have the option to enter an open-label extension (OLE) phase, in which all patients receive treatment with fenebrutinib.

About fenebrutinib

Fenebrutinib is an investigational oral, central nervous system (CNS)-penetrant, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor with an optimized pharmacokinetics (PK) profile. Fenebrutinib can act throughout the body and also cross the blood-brain barrier into the CNS to target chronic inflammation. It is uniquely designed to target relapsing and progressive biology by inhibiting cells in the immune system known as B cells and microglia. Targeting B cells helps control the acute inflammation that causes relapses, while targeting microglia inside the brain addresses the chronic damage that is thought to drive long-term disability progression.

Fenebrutinib is designed to have high potency and reversibility, with a selectivity for BTK 130 times greater than other kinases. This high selectivity highlights fenebrutinib's potential to bind to its intended target without interfering with other kinases. While most current BTK inhibitors are covalent and irreversible, meaning they form a permanent chemical bond with the enzyme, fenebrutinib is non-covalent and reversible, meaning it binds and then eventually releases the enzyme. These design features may help limit off-target effects.

The fenebrutinib Phase III program includes two similarly designed trials in relapsing multiple sclerosis (RMS) (FENhance 1 and 2) with active comparator teriflunomide and the only trial in primary progressive multiple sclerosis (PPMS) (FENtrepid) in which a BTK inhibitor is being evaluated against Ocrevus.

To date, more than 2,700 patients and healthy volunteers have been treated with fenebrutinib in Phase I, II and III clinical programs across multiple diseases, including multiple sclerosis and other autoimmune disorders.

About multiple sclerosis

Multiple sclerosis is a chronic disease that affects more than 2.9 million people worldwide. People with all forms of multiple sclerosis experience disease progression from the beginning of their disease. Therefore, an important goal of treating multiple sclerosis is to slow, stop and ideally prevent progression as early as possible.

Approximately 85% of people with multiple sclerosis are initially diagnosed with relapsing-remitting multiple sclerosis (RRMS). Relapsing forms of the disease (RMS) include RRMS and active secondary progressive MS, and people with RMS experience relapses and worsening disability over time. Primary progressive multiple sclerosis (PPMS) is a debilitating form of the disease marked by steadily worsening symptoms but typically without distinct relapses or periods of remission. Approximately 15% of people with multiple sclerosis are diagnosed with the primary progressive form of the disease. Until the FDA approval of Ocrevus®, there had been no FDA-approved treatments for PPMS and Ocrevus is still the only approved treatment for PPMS. Despite the availability of CD20s, 30% of patients remain on low-efficacy oral therapy today. Slowing or stopping progression while simultaneously stopping relapses remains a high unmet need in MS.

About Genentech in neuroscience

Neuroscience is a major focus of research and development at Genentech. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.

Genentech and Roche are investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, spinal muscular atrophy, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease and Duchenne muscular dystrophy. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.

About Genentech

Founded 50 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.

Indications and Important Safety Information

What is Ocrevus?

Ocrevus is a prescription medicine used to treat:

Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults. It is not known if Ocrevus is safe and effective in children.

Who should not receive Ocrevus?

Do not receive Ocrevus if you have an active hepatitis B virus (HBV) infection.

Do not receive Ocrevus if you have had a life-threatening allergic reaction to Ocrevus. Tell your healthcare provider if you have had an allergic reaction to Ocrevus or any of its ingredients in the past.

What is the most important information I should know about Ocrevus?

Ocrevus can cause serious side effects, including:

Infusion reactions: Infusion reactions are a common side effect of Ocrevus, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of Ocrevus for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you get any of these symptoms: Itchy skin Rash Hives Tiredness Coughing or wheezing Trouble breathing Throat irritation or pain Feeling faint Fever Redness on your face (flushing) Nausea Headache Swelling of the throat Dizziness Shortness of breath Fatigue Fast heartbeat These infusion reactions can happen for up to 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion.

If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

Infection: Infections are a common side effect. Ocrevus increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Serious infections can happen with Ocrevus, which can be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Signs of herpes infection include: cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of Ocrevus. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with Ocrevus until your infection is gone. Hepatitis B virus (HBV) reactivation: Before starting treatment with Ocrevus, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with Ocrevus. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving Ocrevus. Weakened immune system: Ocrevus taken before or after other medicines that weaken the immune system could increase your risk of getting infections. Progressive Multifocal Leukoencephalopathy (PML): PML is a rare brain infection that usually leads to death or severe disability and has been reported with Ocrevus. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with: Thinking Eyesight Strength Balance Weakness on 1 side of your body Using your arms or legs Decreased immunoglobulins: Ocrevus may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels. Before receiving Ocrevus, tell your healthcare provider about all of your medical conditions, including if you:

have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS. have ever had hepatitis B or are a carrier of the hepatitis B virus. have a history of inflammatory bowel disease or colitis. have a history of liver problems have had a recent vaccination or are scheduled to receive any vaccinations. You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with Ocrevus. You should not receive ‘live’ or ‘live-attenuated’ vaccines while you are being treated with Ocrevus and until your healthcare provider tells you that your immune system is no longer weakened. When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with Ocrevus. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with Ocrevus, talk to your healthcare provider. If you have a baby and you received Ocrevus during your pregnancy, it is important to tell your baby’s healthcare provider about receiving Ocrevus so they can decide when your baby should be vaccinated. are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if Ocrevus will harm your unborn baby. You should use birth control (contraception) during treatment with Ocrevus and for 6 months after your last infusion of Ocrevus. Talk with your healthcare provider about what birth control method is right for you during this time. Tell your healthcare provider if you become pregnant while receiving Ocrevus. are breastfeeding or plan to breastfeed. It is not known if Ocrevus passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Ocrevus. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of Ocrevus?

Ocrevus may cause serious side effects, including:

Risk of cancers (malignancies) including breast cancer. Follow your healthcare provider’s instructions about standard screening guidelines for breast cancer. Inflammation of the colon, or colitis: Tell your healthcare provider if you have any symptoms of colitis, such as: Diarrhea (loose stools) or more frequent bowel movements than usual Stools that are black, tarry, sticky or have blood or mucus Severe stomach-area (abdomen) pain or tenderness Liver damage. Ocrevus may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start Ocrevus and while you take Ocrevus if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as: yellowing of the skin and eyes (jaundice) nausea vomiting unusual darkening of the urine feeling tired or weak These are not all the possible side effects of Ocrevus.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088. You may also report side effects to Genentech at (888) 835-2555.

For more information, go to https://www.Ocrevus.com or call 1-844-627-3887.

For additional safety information, please see the full Prescribing Information and Medication Guide.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Scan QR code to install app

Important DisclaimersFXEmpire is owned and operated by Empire Media Network LTD., Company Registration Number 514641786, registered at 7 Jabotinsky Road, Ramat Gan 5252007, Israel. The content provided on this website includes general news and publications, our personal analysis and opinions, and materials provided by third parties. This content is intended for educational and research purposes only. It does not constitute, and should not be interpreted as, a recommendation or advice to take any action, including making any investment or purchasing any product. Before making any financial decision, you should conduct your own due diligence, exercise your own discretion, and consult with competent advisors. The content on this website is not personally directed to you, and we do not take into account your individual financial situation or needs. The information contained on this website is not necessarily provided in real time, nor is it guaranteed to be accurate. Prices displayed may be provided by market makers and not by exchanges. Any trading or other financial decision you make is entirely your own responsibility, and you must not rely solely on any information provided through the website. FXEmpire does not provide any warranty regarding the accuracy, completeness, or reliability of any information contained on the website and shall bear no responsibility for any trading losses you may incur as a result of using such information. The website may include advertisements and other promotional content. FXEmpire may receive compensation from third parties in connection with such content. FXEmpire does not endorse, recommend, or assume responsibility for the use of any third-party services or websites. Empire Media Network LTD., its employees, officers, subsidiaries, and affiliates shall not be liable for any loss or damage resulting from your use of the website or reliance on the information provided herein.Risk DisclaimersThis website contains information about cryptocurrencies, contracts for difference (CFDs), and other financial instruments, as well as about brokers, exchanges, and other entities trading in such instruments. Both cryptocurrencies and CFDs are complex instruments and involve a high risk of losing money. You should carefully consider whether you understand how these instruments work and whether you can afford to take the high risk of losing your money. FX Empire encourages you to conduct your own research before making any investment decision and to avoid investing in any financial instrument unless you fully understand how it works and the risks involved.

Corporación América Airports remains undervalued and is enjoying above-average traffic growth. January traffic rose 8.8% year-over-year, driven by 14.8% international growth and a particular 21.8% surge in Argentina's high-margin international traffic. Analyst consensus projects 10% revenue and 41% EPS growth for 2026, with actual revenue likely to exceed estimates due to new concessions and accelerating traffic.

What happenedAccording to a SEC filing dated February 17, 2026, Lightspeed Management Company initiated a new position in Kodiak AI (KDK +1.21%) by purchasing 7,340,475 shares during the fourth quarter. The estimated transaction value was $80.16 million.

What else to knowThis new position represents 5.74% of the fund’s 13F reportable AUM as of December 31, 2025.

Top five holdings after the filing:

NASDAQ:NAVN: $852.66 million (61.1% of AUM)NYSE:NOW: $273.22 million (19.6% of AUM)NASDAQ:KDK: $80.16 million (5.74% of AUM)NYSE:BLND: $70.31 million (5.0% of AUM)NASDAQ:PSNL: $64.96 million (4.7% of AUM)As of Feb. 27, 2026, shares of Kodiak AI were priced at $8.40, up 5.66% since the company went public in September 2025 and outperforming the S&P 500 by 1.51 percentage points in that time.

Company OverviewMetricValuePrice (as of market close February 27, 2026)$8.40Market Capitalization$1.52 billionRevenue (TTM)$16.5 millionNet Income (TTM)-$526 millionCompany SnapshotKodiak AI is a technology company specializing in autonomous driving solutions for commercial and defense applications.

The company leverages a proprietary multi-sensor architecture to deliver scalable AI-powered navigation for complex environments. Its focus on high-reliability autonomy positions it as a differentiated provider in the evolving autonomous vehicle market.

It targets commercial transportation, defense contractors, and industrial fleet operators seeking advanced autonomous vehicle capabilities.

What this transaction means for investorsKodiak AI is a relatively new stock, going public just six months ago. Younger stocks can be riskier in some cases because there’s little historical data to examine, especially regarding how they’ve weathered downturns. Before going public in 2025, the company was launched in 2018.

This makes Lightspeed’s big swing on Kodiak AI even more notable. The stock is now the fund’s third-largest holding, signally a fairly strong conviction in Kodiak’s long-term growth potential.

Kodiak AI is a relatively small player in the self-driving-car space, but it’s already captured the industry’s attention. Last month, Northland named the stock one of its top picks of 2026, with a price target of $17. Cathie Wood’s ARK Invest has also consistently increased its stake in the company.

Kodiak’s long-term success will depend largely on how the autonomous trucking industry fares. If Driving as a Service becomes more widespread, this company could be poised for significant growth.

Katie Brockman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends ServiceNow. The Motley Fool has a disclosure policy.

Chinese automakers broadly recorded a sharp drop in sales in February as demand in the world's largest auto industry waned during the Lunar New Year month.

VanEck BDC Income ETF is the largest, most liquid BDC ETF but is highly concentrated in a few names. Recent market dislocation has driven BDC and alternative asset manager equities down 11–12%, raising questions about credit quality and diversification. BIZD's top three holdings account for over 45% of assets, limiting true diversification and making it a concentrated bet rather than a broad BDC play.

Crown Castle (CCI) remains a soft ‘buy' as the $8.5B asset sale should substantially improve leverage and capital allocation flexibility. Despite recent revenue and profit declines, CCI's core tower business remains cash-generative and defensible, with organic growth offsetting some contract headwinds. The DISH Wireless contract termination poses a near-term $220M revenue hit, but interest expense savings and cost cuts are expected to lift adjusted FFO post-sale.

What happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, FourWorld Capital Management LLC established a new position in Sable Offshore Corp. (SOC +4.30%) by acquiring 8,105,608 shares. The estimated value of this trade was $73.11 million.

What else to knowThis was a new position for the fund, with Sable Offshore now accounting for 62.9% of reportable AUM as of December 31, 2025.

Top holdings after the filing:

NYSE:SOC: $73.11 million (62.9% of AUM)NYSEMKT:IWM: $6.15 million (5.3% of AUM)NYSE:BMY: $5.39 million (4.6% of AUM)NASDAQ:EVLV: $5.13 million (4.4% of AUM)NYSEMKT:XLE: $4.47 million (3.85% of AUM)As of February 27, 2026, Sable Offshore shares were priced at $8.25, down 72.92% over the past year and underperforming the S&P 500 by 86.44 percentage points.

Company overviewMetricValuePrice (as of market close Feb. 27, 2026)$8.25Market capitalization$1.20 billionNet income (TTM)-$364 millionCompany snapshotSable Offshore is an energy company focused on offshore oil and gas production, leveraging a portfolio of federal leases totaling approximately 76,000 acres.

The company engages in the production and sale of crude oil and natural gas through offshore California platforms and an onshore processing facility, and it serves energy markets in the United States.

What this transaction means for investorsFourWorld took a major swing on Sable Offshore. The stock is now the firm’s top holding, comprising more than 60% of its portfolio. Considering that all other top holdings make up 5% or less of the fund, FourWorld holds a major conviction in Sable Offshore.

This stock has not been without its challenges. Falling by more than 70% over the last 12 months, the company has faced major legal challenges. Late last year, federal regulators approved the restart of its Las Flores pipeline in California, only for environmental groups to immediately file a lawsuit to halt the restart.

More recently, a Santa Barbara judge ruled against Sable Offshore’s bid to restart the pipeline, further halting its progress. This legal battle could be long and drawn out, increasing the stock’s potential for volatility going forward.

Because the stock has plunged over the last year, it is a more affordable buy. However, much of its success will depend on how it fares with its many legal challenges. While it may have long-term growth potential, it’s also a high-risk buy right now.

Katie Brockman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Bristol Myers Squibb. The Motley Fool has a disclosure policy.

MercadoLibre (MELI +1.01%) is an e-commerce powerhouse operating in Latin America and serving 18 countries in the region. It regularly reports strong growth across its business, which includes a large fintech segment, and it has a massive long-term opportunity.

It has a four-digit price tag, trading at $1,768 per share as of this writing. Is it headed to $2,000?

Image source: Getty Images.

Creating a digital revolution in Latin America E-commerce penetration in Latin America is about half that of the U.S., and MercadoLibre is trying to change that, launching new products and improving its value proposition to create the shift. Management said that it sees no reason why the market shouldn't increase, and that its gross merchandise volume (GMV) "could be multiple times larger over the long term."

It starts with the customers. MercadoLibre had 83 million unique active buyers as of the end of 2025, a 24% year-over-year increase. As more customers join the platform, more merchants want to be on it, too, creating a flywheel effect. That brings on more products, and as more business is transacted, the bottom line increases, too.

The fintech segment is complementary to the e-commerce platform, with the Mercado Pago digital wallet one option for paying for purchases. But it has developed into a formidable stand-alone business with nearly 78 million monthly active users as of the end of 2025, a 27% increase, and it offers a large assortment of digital financial services.

In the fourth quarter, management said that it's sacrificing the bottom line right now by investing in new projects that position it for the long term, and that send the price down.

Today's Change

(

1.01

%) $

17.61

Current Price

$

1758.49

Can MercadoLibre stock get back to $2,000? MercadoLibre stock was higher than $2,600 in May last year, and it's down 32% from its high. Investors have had several concerns over the past few months, including a volatile economy in Brazil and the recent margin pressure.

To get back to $2,000, it only needs to gain 14%. Since the stock is fairly cheap at the current price, trading at a forward one-year price-to-earnings ratio of 22 and a price-to-free-cash-flow ratio of 15, it could easily surpass $2,000 if it reports a higher than 14% increase in earnings in its next quarterly results without becoming more expensive. If the market continues to sour on it, it may take longer, but there's a lot to be confident about long-term, and I anticipate it going a lot higher.

BARCELONA, Spain--(BUSINESS WIRE)-- #5G--Aptiv PLC (NYSE: APTV) and Wind River, an Aptiv company and global leader in software for the intelligent edge, is unveiling a proof-of-concept showcasing a mobile-network Vehicle-to-Everything (V2X) solution for sharing of sensor data between vehicles to support advanced safety and automation features leveraging the Verizon Business connected-driving platform Edge Transportation Exchange. Showcasing at MWC Barcelona, the demonstration highlights how vehicles.

LOS ANGELES, March 02, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Alibaba Group Holding Ltd, (“BABA" or the "Company") (NYSE:BABA) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. 

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: [email protected], to discuss their legal rights, or join the case via https://portnoylaw.com/alibaba-group-holding-ltd. The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.

Palantir’s stock price fell $13.98, or 7.5%, to close at $173.07 per share on October 3, 2025, thereby injuring investors. This occurred following a Reuters report published on October 3, 2025, detailing an Army memo from early September that raised concerns about NGC2, a battlefield communications platform developed by Anduril Industries Inc. and Palantir. The memo alleged the system was flawed, citing “critical deficiencies in fundamental security controls, processes, and governance” and stating that the companies' communications networks were susceptible to “insider threats, external attacks, and data spillage.”

The Portnoy Law Firm represents investors in pursuing claims caused by corporate wrongdoing. The Firm’s founding partner has recovered over $5.5 billion for aggrieved investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Lesley F. Portnoy, Esq.
Admitted CA, NY and TX Bar
[email protected]
310-692-8883
www.portnoylaw.com 

Attorney Advertising

THOR Industries (THO) remains a 'hold', as industry headwinds and economic risks offset its attractive valuation and market leadership. Recent results showed revenue rising to $2.39B and net profit swinging to $21.7M, driven by strong wholesale motorized RV demand. Management's 2026 guidance is cautious, projecting revenue of $9–$9.5B and EPS of $3.75–$4.25, below 2025 levels.

CORNING, N.Y.--(BUSINESS WIRE)--Corning Incorporated (NYSE: GLW) today announced the launch of Corning® Gorilla® Glass Ceramic 3, the toughest Gorilla Glass Ceramic ever made. Designed to help deliver enhanced durability across a device's lifetime, Gorilla Glass Ceramic 3 will be featured on Motorola's upcoming razr fold device. “We engineer our materials with longevity in mind, not just initial performance,” said Lori Hamilton, Division Vice President & Business Technology Director, Cornin.

Vancouver, British Columbia--(Newsfile Corp. - March 2, 2026) - Silver One Resources Inc. (TSXV: SVE) (OTCQX: SLVRF) (FSE: BRK1) ("Silver One" or the "Company") is pleased to announce that has commenced a core drilling program that will provide essential geotechnical data for its Candelaria Silver Project in Nevada. In parallel, the company has engaged Call & Nicholas, Inc., a globally recognized geotechnical engineering firm, to conduct a pre-feasibility level ("PFS") pit-slope stability study in support of a conceptual PFS open-pit design. This work represents a major advancement toward the Company's planned PFS, scheduled for completion in Q4 2026.

The drilling program includes nine HQ-diameter (63.5 mm) core holes totaling approximately 1,900 metres, strategically positioned within and along the margins of the proposed open-pit footprint (See Figure 1). The resulting geotechnical data will guide slope design, optimize mine engineering, and support long-term operational safety and efficiency.

Candelaria stands out as one of the most compelling emerging silver projects in the United States. A former producing mine with a long history of successful operations, the project benefits from previous permitting, excellent infrastructure (including power and water), road access year-round, and significant potential for resource expansion along strike and at depth. These advantages position Candelaria as a rare combination of scale, simplicity, and growth opportunity in a Tier-1 jurisdiction.

The project currently hosts a substantial resource potentially suitable for open-pit development, including:

Measured & Indicated ("M&I"): 22,070,000 tonnes grading 94 g/t Ag and 0.20 g/t Au, containing 66.754 million ounces of silver and 141,400 ounces of gold, or 70.84 million ounces AgEq

Inferred: 2,960,000 tonnes grading 68 g/t Ag and 0.18 g/t Au, containing 6.462 million ounces of silver and 17,000 ounces of gold, or 7.00 million ounces AgEq

This open-pit resource constitutes only a portion of the overall property resources, which also include two heap leach pads hosting substantial amounts of silver and gold. The current global resource for the property amounts to 108.18 million ounces AgEq M&I plus 29.53 million ounces AgEq Inferred (See Table 1 and 2; Company news release dated May 6, 2025; and complete details in the NI 43-101 Technical Report "Mineral Resource Estimate on the Candelaria Property" dated April 30, 2025, filed on SEDAR+).

Gregory Crowe, President and CEO, commented: "Launching the geotechnical drilling program and commissioning Call & Nicholas for the PFS-level slope-stability study marks a major milestone in de-risking and advancing Candelaria. This work provides the engineering backbone for our open-pit design and is essential to delivering a robust pre-feasibility study. With its strong resource base, past-producing history, excellent infrastructure, and clear potential for expansion, Candelaria continues to demonstrate why it is one of the most exciting silver development projects in Nevada."

Figure 1. Planned geotechnical drill-hole location map (UTM NAD83 11S). Blue line shows the perimeter of the proposed pit design.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/4730/285851_e18aa4234463c854_001full.jpg

Table 1. Candelaria in-ground, underground, and stockpiles mineral resource estimates. The mineral resource estimate has an Effective Date of April 30, 2025.

Table 2. Candelaria Leach Pad mineral resources. The mineral resource has an Effective Date of August 6, 2020.

Qualified Persons

The technical content of this news release, not related to the mineral resource, has been reviewed and approved by Robert M. Cann, P. Geo, a Qualified Person as defined by National Instrument 43-101 and an independent consultant to the Company.

About Silver One

Silver One is focused on the exploration and development of quality silver projects. The Company holds 100% interest in its flagship project, the past-producing Candelaria Mine located in Nevada. Potential reprocessing of silver from the historic leach pads at Candelaria provides an opportunity for possible near-term production. Additional opportunities lie in previously identified high-grade silver intercepts down-dip and potentially increasing the substantive silver mineralization along-strike from the two past-producing open pits.

The Company owns 636 lode claims and five patented claims on its Cherokee project located in Lincoln County, Nevada, host to multiple silver-copper-gold vein systems, traced to date for over 11 km along-strike.

Silver One also owns a 100% interest in the Silver Phoenix Project. The Silver Phoenix Project is a very high-grade native silver prospect that lies within the "Arizona Silver Belt," immediately adjacent to the prolific copper producing area of Globe, Arizona.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Silver One cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond Silver One's control. Such factors include, among other things: risks and uncertainties relating to Silver One's limited operating history, ability to obtain sufficient financing to carry out its exploration and development objectives on the Candelaria Project, obtaining the necessary permits to carry out its activities and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Silver One undertakes no obligation to publicly update or revise forward-looking information.

NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/285851

Source: Silver One Resources Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Prefer us on Google

Hayes claims every US president since 1985 launched Middle Eastern military action, followed by Federal Reserve monetary easing.He advises investors to wait for actual Fed rate cuts before buying Bitcoin and select altcoins.Bitcoin trades near $66,200, down 47% from its October 2025 all-time high, with fear sentiment at extremes.BitMEX co-founder Arthur Hayes published a new essay on March 2 arguing that prolonged US military engagement with Iran would increase the likelihood of Federal Reserve rate cuts and money printing, ultimately driving Bitcoin higher.

His thesis rests on a four-decade pattern: every major US military campaign in the Middle East has been followed by Fed easing, and he expects Iran to be no different.

War and the Fed: A Recurring PatternIn “iOS Warfare,” Hayes presented a historical analysis linking US military operations in the Middle East to subsequent monetary easing by the Fed. He noted that every US president since 1985 has launched missile strikes or full-scale wars against Middle Eastern countries, and that the Fed consistently lowered interest rates in the aftermath.

Hayes cited three precedents. During the 1990 Gulf War under President George H.W. Bush, the Fed held rates steady at its first post-war meeting but signaled easing was likely if the conflict dragged on. The central bank cut rates at its November and December 1990 meetings, even as oil-driven inflation persisted.

After the September 11 attacks in 2001, Fed Chair Alan Greenspan pushed through an emergency 50-basis-point rate cut, citing downward pressure on asset prices and the need to restore economic confidence. The wars in Iraq and Afghanistan that followed were accompanied by an extended easing cycle.

Under President Obama’s 2009 troop surge in Afghanistan, rates were already at zero, and quantitative easing was underway, leaving no further room for cuts.

Turning to the present, Hayes framed Trump’s apparent endorsement of regime change in Iran as following the same pattern. He argued that Iranian regime change has been a bipartisan objective among US policymakers since 1979, giving the Fed political cover to ease monetary policy to finance the effort.

Hayes supported his argument with a chart showing that the percentage of the federal budget allocated to the Department of Veterans Affairs rose twice as fast as aggregate federal spending since 1985, alongside declining effective Fed Funds Rates following major military engagements.

Wait for the CutDespite his bullish long-term outlook, Hayes advised caution in the near term. He recommended investors wait for the Fed to actually cut rates or begin printing money before adding exposure to Bitcoin and select altcoins.

“We do not know how long Trump will remain interested in spending billions, if not trillions, of dollars reshaping Iran’s politics to his liking,” Hayes wrote. “The prudent action is to wait and see.”

Bitcoin was trading around $66,200 at the time of publication, down nearly 30% year-over-year and roughly 47% below its all-time high of $126,000 reached in October 2025. The coin has fallen for five consecutive months, with the Crypto Fear and Greed Index stuck in extreme fear territory.

Disclaimer

In adherence to the Trust Project guidelines, BeInCrypto is committed to unbiased, transparent reporting. This news article aims to provide accurate, timely information. However, readers are advised to verify facts independently and consult with a professional before making any decisions based on this content. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Bitcoin pushed back above $67,000 even as geopolitical tensions between the United States and Iran rattled global markets and pressured risk assets.

The rebound has surprised traders who expected a deeper drawdown under heightened macro uncertainty.

The asset dropped to as low as $60,030 in the early hours of the 28th of February after tensions escalated and fear spread across financial markets.

Yet, instead of extending its losses, Bitcoin [BTC] stabilized and advanced toward $68,000, recovering a significant portion of its decline within hours.

Such resilience appears counterintuitive. Historically, geopolitical escalations have triggered sustained risk-off reactions, often leading to prolonged weakness in speculative assets.

Bitcoin’s swift rebound therefore raises a critical question: does this strength reflect genuine accumulation, or is it a temporary rally within a broader corrective phase?

A familiar pattern from 2022? Market analyst Benjamin Cowen has urged caution. According to his recent assessment, the current price structure resembles Bitcoin’s behavior during the 2022 Russia–Ukraine conflict.

In 2022, Bitcoin initially sold off as geopolitical tensions intensified. It then staged a sharp rebound that many interpreted as the start of a recovery.

However, that rebound formed a lower high before the market resumed its downtrend.

The subsequent decline proved severe. Bitcoin fell approximately 67%, sliding from around $48,189 to a cycle low near $15,476.

Source: TradingView

Cowen argues that the present setup may be tracing a similar fractal.

If the pattern holds, Bitcoin could experience a relief rally into the $70,000–$84,000 range before forming another lower high and extending its broader correction.

Cowen noted,

“Bear markets tend to take a while to play out.”

He added that even if March delivers upward momentum, the move may resemble the 2022 lower-high structure rather than confirm a sustained bull cycle.

Cowen has maintained a cautious long-term stance on Bitcoin for months, and this latest analysis reinforces his view that the market may not have completed its corrective phase.

Trading below realized price shifts the risk balance Beyond technical structure, on-chain data adds another layer of concern.

At the time of analysis, Bitcoin traded below this adjusted realized price, estimated near $72,700. Historically, this level has acted as a structural support zone during expansion phases.

In both June and September 2023, price found stability around similar cost-basis levels before advancing.

Source: CryptoQuant

However, when Bitcoin last broke below this threshold in May 2022, the market endured sustained weakness until March 2023 before regaining stability.

Trading below the realized price often indicates that a large portion of active holders sit at an unrealized loss.

That condition can dampen demand, reduce conviction, and increase the likelihood of supply entering the market during rebounds.

If historical behavior repeats, Bitcoin could face an extended period of consolidation or gradual decline before establishing a durable recovery.

Liquidation clusters heighten volatility risk Derivatives positioning further complicates the outlook. Liquidation data suggests the market holds significant leveraged exposure on both sides, increasing the probability of sharp, forced moves.

On the upside, $68,596 represents a high-interest zone where substantial 50x and 100x short positions are concentrated.

A decisive breakout above this level could trigger cascading short liquidations and amplify upward momentum.

On the downside, $65,656 carries similar leverage concentration among long positions. A breakdown below this level could force liquidations and accelerate selling pressure.

Source: CoinGlass

With leverage elevated and geopolitical risk unresolved, Bitcoin sits in a structurally sensitive position. A decisive move in either direction could trigger a volatility cascade.

For now, the rally above $67,000 reflects resilience.

Whether it marks genuine strength or a classic bull trap will likely depend on whether Bitcoin can reclaim its realized price and avoid forming another lower high in the weeks ahead.

Final Summary Bitcoin’s recovery comes despite rising geopolitical tensions between the United States and Iran. The asset now trades below its adjusted cost basis, a development that historically signals structural weakness.

In brief HYPE rose about 6% even as Iran headlines drove weekend volatility. Hyperliquid absorbed early volume as price moves formed before traditional futures reopened. Weekend shocks may turn always-on perps into a repeat venue for early risk pricing and fee growth, Decrypt was told. As tensions escalated over Iran-related headlines this weekend, Hyperliquid’s HYPE token rose about 6% as traders turned to the always-on decentralized perpetuals platform to express risk while many traditional markets were closed.

Bitcoin and other risk assets fell as Iran-related tensions escalated, while oil and gold moved higher amid a broader risk-off shift. Volatility rose, and funding rates turned negative across crypto derivatives markets as traders adjusted positioning.

Hyperliquid is a decentralized exchange that lets traders buy and sell perpetual futures contracts directly on-chain without using a centralized intermediary.

Its native token, HYPE, fell to about $26.2 at the end of February, in line with the broader market pullback, before surging to roughly $32 as volatility picked up on Sunday.

The token is up about 25% year to date, though it remains well below its September peak near $58, per CoinGecko data.

Trading volume over the last 24 hours for the exchange reached a near one-month high on Saturday, rising to a peak of $200 million before dissipating as traders digested the risk premium to global energy markets.

Always-on tradingHyperliquid was one of the few venues open and liquid as volatility picked up over the weekend, drawing trading activity at a time when equity futures and many centralized crypto platforms were either closed or operating with thinner books.

“As a decentralized perpetuals platform, it was one of the few venues actually open and liquid when the Iran headlines hit, and in a weekend event where centralized venues are closed off to face thin liquidity,” Ryan McMillin, chief investment officer at Merkle Tree Capital, told Decrypt.

Geopolitical shocks “make the case for non-custodial, always-on trading infrastructure,” McMillin added, noting how HYPE appears to sit “at an interesting intersection.”

Hyperliquid’s token “benefits both from volume-driven fee revenue during chaos events and from any broader rotation away from centralised exchange risk,” he said. “It's worth watching whether weekend crisis volume is becoming a structural tailwind rather than a one-off.”

For HYPE, this ties geopolitical shocks directly to trading volume and fee activity, supporting the view that off-hours crises may become a repeat source of demand.

First responseDecentralized platforms like Hyperliquid’s are increasingly serving as “the first-response venue for geopolitical risk,” Dominick John, analyst at Kronos Research, told Decrypt.

“Institutions leverage these always-on markets to anticipate moves in conventional venues, using on-chain perpetuals to hedge before broader markets open,” John explained, adding that such a function positions decentralized venues “for early risk pricing.”

Weekend geopolitical shocks provide decentralized perpetuals exchanges “a structural edge” that captures “risk-driven flow while TradFi sleeps,” he added.

While platforms like Hyperliquid could serve that purpose, most other perpetual decentralized exchanges, including its own HIP-3 markets, would still need to “achieve much deeper order book liquidity to onboard institutional traders,” Siwon Huh, researcher at Four Pillars, told Decrypt.

On Hyperliquid, new markets require HYPE to be staked, and much of the platform’s fees go toward HYPE buybacks, meaning volatility and trading growth can directly increase demand for the token, which has also shown lower correlation to Bitcoin than many other altcoins, he explained.

“For now, they appear to have already established themselves as highly useful exchanges at the retail level,” Huh said, adding that the weekend geopolitical shocks are likely to “capture demand from liquidity providers requiring hedging at a much larger scale.”

Daily Debrief NewsletterStart every day with the top news stories right now, plus original features, a podcast, videos and more.

On Monday, March 2, the ISM Manufacturing report can quickly reset the growth narrative. On Wednesday, March 4, traders get ADP private payrolls and the ISM Services report, which often shapes positioning into the labor data.

The main event is Friday, March 6, when the Bureau of Labor Statistics releases the US jobs report (Nonfarm Payrolls) at 0800 ET, a print that frequently moves Treasury yields and the dollar immediately.

Bitcoin often trades like a high-beta “liquidity” asset when rates move. Hot data can push yields higher and make it harder for BTC to sustain rallies.

Cooler data can help by reviving rate-cut hopes, but the reaction can still be choppy if traders read the weakness as a growth scare rather than a clean disinflation signal.

Bitcoin Pennant Keeps $52,000–$51,800 Target in Play Bitcoin’s rebound is also unfolding inside what looks like a bear pennant on the daily chart, forming after the sharp drop from the $73,000–$74,000 area into the $63,000 low.

XRP price started a recovery wave above $1.3820 but failed near $1.420. The price is now consolidating and might aim for a fresh move above $1.420.

XRP price started a recovery wave above the $1.3820 zone. The price is now trading below $1.3880 and the 100-hourly Simple Moving Average. There was a break above a bearish trend line with resistance at $1.360 on the hourly chart of the XRP/USD pair (data source from Kraken). The pair could continue to move up if it settles above $1.40. XRP Price Faces Resistance XRP price remained supported above $1.30 and started a recovery wave, like Bitcoin and Ethereum. The price was able to climb above $1.3250 and $1.350 to enter a short-term positive zone.

There was also a move above the 50% Fib retracement level of the downward move from the $1.4936 swing high to the $1.2702 low. Besides, there was a break above a bearish trend line with resistance at $1.360 on the hourly chart of the XRP/USD pair.

The bulls even pushed the price above $1.3820 but they struggled to keep the price above $1.40. The price is now trading below $1.3880 and the 100-hourly Simple Moving Average. If there is a fresh upward move, the price might face resistance near the $1.3820 level.

Source: XRPUSD on TradingView.com The first major resistance is near the $1.4080 level or the 61.8% Fib retracement level of the downward move from the $1.4936 swing high to the $1.2702 low.  A close above $1.4080 could send the price to $1.420. The next hurdle sits at $1.440. A clear move above the $1.440 resistance might send the price toward the $1.4550 resistance. Any more gains might send the price toward the $1.50 resistance.

Another Drop? If XRP fails to clear the $1.4080 resistance zone, it could start a fresh decline. Initial support on the downside is near the $1.340 level. The next major support is near the $1.3220 level.

If there is a downside break and a close below the $1.3220 level, the price might continue to decline toward $1.30. The next major support sits near the $1.2880 zone, below which the price could continue lower toward $1.2720.

Technical Indicators

Hourly MACD – The MACD for XRP/USD is now losing pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for XRP/USD is now above the 50 level.

Major Support Levels – $1.340 and $1.3220.

Major Resistance Levels – $1.3820 and $1.4080.

Breaking Signal·Market Impact: Low

Hyperliquid jumped 3.31% to $31.89, topping the gainers chart, according to CoinGecko data. Provenance Blockchain led the downside with a 10.76% drop to $0.0157 as decliners outpaced risers among larger caps. Rounding out the winners were MemeCore, LEO Token, Ondo US Dollar Yield and Beldex, while Decred, Pepe, Toncoin and Render lagged.

Top Gainers Hyperliquid (HYPE) rose 3.31% to $31.89, lifting its market capitalization to $7.60B. The token powers Hyperliquid, a decentralized derivatives venue built around an order book model and onchain settlement. Perps-focused platforms have seen persistent trader interest, keeping attention on exchange tokens tied to liquidity and fee capture. Liquidity depth and funding dynamics often steer flows in this corner of the market, and HYPE tracked that bid today.

MemeCore (M) added 2.68% to $1.51, bringing its market cap to $2.62B. M is the native token of the MemeCore ecosystem. No specific news has been tied to the move. The advance came alongside a mixed session for higher-beta tokens.

LEO Token (LEO) advanced 1.71% to $9.14, with a market cap of $8.42B. LEO is the utility token for iFinex, offering trading fee discounts and other benefits on Bitfinex. The token’s supply is subject to a buyback-and-burn mechanism funded by iFinex revenues. The steady uptick tracked a mild bid for exchange-linked assets.

Ondo US Dollar Yield (USDY) inched up 1.04% to $1.12, valuing the token at $711.83M. USDY is an Ondo Finance product that tokenizes U.S. dollar yield exposure, designed to provide onchain access to yield-bearing instruments. Traders pointed to broader altcoin rotation as stable-value assets posted small premiums. The move kept USDY above par while maintaining its core yield narrative.

Beldex (BDX) gained 1.00% to $0.0804, lifting market cap to $611.60M. BDX underpins a privacy-focused network with a masternode architecture and tools aimed at confidential transactions. The asset often moves independently from large-cap cycles given its niche. Today’s incremental climb extended a period of range-bound trading.

Top Losers Provenance Blockchain (HASH) fell 10.76% to $0.0157, putting its market capitalization at $865.71M. HASH fuels Provenance, a chain geared toward financial services, asset tokenization, and onchain banking workflows. The slide erased recent gains as sellers pressed the bid in afternoon trading. Liquidity pockets around prior support gave way, accelerating the drawdown.

Decred (DCR) retreated 7.82% to $30.51, with market cap at $529.41M. Decred combines proof-of-work and proof-of-stake for governance and security, backed by a community treasury. The drawdown marked a rejection of intraweek strength near resistance. Volatility for governance-focused coins remained elevated relative to majors.

Pepe (PEPE) dropped 7.63% to $0.000003, bringing its market cap to $1.45B. The frog-themed memecoin trades with high beta to risk appetite and liquidity cycles. A pullback in momentum names pressured PEPE after recent speculative bursts. Funding and open interest resets often amplify swings in this segment.

Toncoin (TON) slipped 7.01% to $1.20, valuing the network at $2.94B. TON is tied to The Open Network, which pursues high-throughput payments and applications with ties to Telegram’s ecosystem. The selloff reflected risk-off flows into larger caps and stables during the session. Prior support levels offered limited cushion as volumes thinned.

Render (RENDER) declined 6.04% to $1.36, with market cap at $704.93M. Render powers a decentralized GPU rendering marketplace for artists and AI workloads. After a strong multi-week run, the token faced profit-taking as appetite cooled for compute-linked assets. The retrace aligned with reduced bid depth across mid-cap infrastructure names.

Market Outlook Dispersion widened today, with the top gainer up 3.31% while the biggest loser shed 10.76%. Gains skewed modest, led by exchange and utility names, as the downside clustered in tokens sensitive to liquidity and momentum.

Into the week, watch Bitcoin’s range for cues on alt liquidity, and monitor any scheduled macro prints such as U.S. labor data for volatility spillover. Headlines around exchange listings, derivatives funding shifts, or protocol upgrades could quickly reprice the winners-and-losers board.

SourcesCoinGecko

This article was written with AI assistance and reviewed by the The Currency analytics editorial team. Information presented is sourced from publicly available reports. The Currency analytics strives for accuracy but cannot guarantee completeness. This article does not constitute financial advice.

Post Views: 1

Bitcoin price started a decent increase above $66,000. BTC is now consolidating above $66,000 and might aim for more gains above $67,200.

Bitcoin started a fresh increase after it settled above the $65,500 support. The price is trading below $67,000 and the 100 hourly simple moving average. There is a bearish trend line forming with resistance at $67,000 on the hourly chart of the BTC/USD pair (data feed from Kraken). The pair might dip again if it trades below the $65,500 and $65,000 levels. Bitcoin Price Faces Key Resistance Bitcoin price managed to form a base above the $63,500 zone. BTC started a fresh increase and was able to surpass the $64,500 resistance zone.

The price even rallied above the $67,000 resistance. Finally, the bears appeared near $68,000. A high was formed at $68,180, and the price recently corrected some gains. There was a move below the 50% Fib retracement level of the upward move from the $63,030 swing low to the $68,181 high.

Bitcoin is now trading below $67,000 and the 100 hourly simple moving average. If the price remains stable above $65,000, it could attempt a fresh increase. Immediate resistance is near the $67,000 level. There is also a bearish trend line forming with resistance at $67,000 on the hourly chart of the BTC/USD pair.

Source: BTCUSD on TradingView.com The first key resistance is near the $68,200 level. A close above the $68,200 resistance might send the price further higher. In the stated case, the price could rise and test the $69,500 resistance. Any more gains might send the price toward the $70,000 level. The next barrier for the bulls could be $70,500 and $71,200.

Downside Continuation In BTC? If Bitcoin fails to rise above the $67,000 resistance zone, it could start another decline. Immediate support is near the $65,500 level. The first major support is near the $65,000 level or the 61.8% Fib retracement level of the upward move from the $63,030 swing low to the $68,181 high.

The next support is now near the $64,250 zone. Any more losses might send the price toward the $64,000 support in the near term. The main support now sits at $63,000, below which BTC might struggle to recover in the near term.

Technical indicators:

Hourly MACD – The MACD is now losing pace in the bullish zone.

Hourly RSI (Relative Strength Index) – The RSI for BTC/USD is now above the 50 level.

Major Support Levels – $65,500, followed by $65,000.

Major Resistance Levels – $67,000 and $68,200.

Journalist

Posted: March 2, 2026

Jupiter [JUP] bounced back from a $0.14 slip and climbed to a two-week high of $0.176. In doing so, Jupiter flipped its short-term moving averages, EMA20, indicating strong upside momentum. 

As of this writing, the altcoin traded at $0.172, up 17.13% on the daily charts, adding to its weekly gains. The explosive price jumps confirm the strengthening momentum across all market participants.

In fact, after JUP dropped to a low of $0.14, it saw renewed demand with new users taking the opportunity to take positions. Active Daily Addresses rose to 13.3k, up 200, indicating increased network usage. 

Source: Santiment

Jupiter sees fresh capital inflows Interestingly, investors took the recent market weakness as an opportunity to deploy capital. On the Futures side, the altcoin recorded $25.01 million in inflows compared to $23.05 million in outflows. 

As a result, its netflow rose 194.3% to $1.96 million, reflecting increased demand for Futures positions. 

Source: CoinGlass

Meanwhile, the altcoin’s Open Interest rose 22% to $44.07 million, while Derivatives Volume climbed 53% to $101 million. A rise in these two metrics further validated increased demand for Futures positions. 

However, market participants on Binance and OKX seem positioned for another pullback. This is because the altcoin’s Long/Short Ratio was held below 1, around 0.99, with Binance at 0.93 and OKX at 0.89. 

Source: CoinGlass

A ratio below 1 indicates a higher demand for short positions, suggesting most participants expect another slip.

Is the upside momentum sustainable? Jupiter showed strong momentum, as investors jumped into the market to accumulate at a discount following the recent broader market slip.

As a result, the altcoin’s upside momentum strengthened. Its Relative Strength Index (RSI) rose to 55, edging into bullish territory.

At the same time, the price flipped EMA20 and is currently testing EMA50, indicating strong upside momentum.

When these momentum indicators reach such levels, it signals buyer confidence and often follows higher prices.

Source: TradingView

Therefore, if the prevailing sentiment holds and more capital flows, JUP will flip EMA50 at $0.17, flip $0.2, and eye EMA100 at $0.21.

However, this bullish outlook faces a major risk and could hinder a possible trend continuation. On the spot market, after Jupiter rebounded, investors who had been underwater rushed to cash out.

Source: CoinGlass

The altcoin’s exchange inflow outpaced outflows, as Spot Netflow climbed 145% to $677k. The market recorded $5.6 million in inflows compared to $4.9 million in outflows.

If this selling spree continues and intensifies, a market pullback remains imminent. Thus, JUP could drop to $0.14 again before attempting another pullback.

Final Summary JUP surged 17%, touching a local high of $0.176 amid broader market recovery. Jupiter saw renewed speculative demand, but the pullback threat remained as profit takers rushed to cash out.

Journalist

Posted: March 2, 2026

Useless Coin [USELESS] was among the best-performing memecoins during the day as the crypto markets rebounded following the death of Iran’s supreme leader. USELESS rallied over 17% in 24 hours, outpacing the entire crypto market, which rose by 4.71%.

As war tensions cooled off, capital was flowing into the memecoin alongside others like Bitcoin [BTC], which shot up to $67K. Hence, who was responsible for this capital injection that day?

Capital inflows surging Data from Nansen AI showed that buying and liquidity had exploded over the past day.

For instance, the Top PnL traders loaded $75K in net flows, which was a spike of 3x from the average daily inflows. The simultaneous purchases by four wallets in this bracket indicated coordinated conviction.

Whales were not left behind either.

Their net flow of $60K exceeded their normal buying by 1.6X as holdings grew by $2 million, reaching $77 million. These orders came in bits that averaged over 340K USELESS coins for each whale.

Source: Nansen AI

New capital was also embracing USELESS despite its “futility.”

This is because fresh wallets added $351K, which was a spike of more than 220%.

Additionally, the holdings of 4.1 million USELESS tokens remained untouched by smart money. The exchange outflows and dormancy in smart money wallets indicated less immediate sell pressure.

Wintermute supported the memecoin’s active trading liquidity. This was despite the selling of bots when the price hit $0.045.

All this capital inflow explained why the memecoin rallied so hard. Will the rally be sustainable going forward?

Will USELESS Coin continue to see more upside? On the charts, the day’s rally was evident from a low of $0.036 to just above $0.045. The lower support level of the sideways range at $0.036 coincided with an order block created on the 14th of February.

The whole range movement was about 29%, though USELESS had started to pull back at press time. The memecoin looked headed toward $0.036 again, and seller momentum was building, as seen in the MACD.

Additionally, the Choppiness Index (CHOP) was rising, at 49.26, indicating the current rally was losing its trendiness. This reinforced that USELESS was still trading in a sideways range.

Breaking above the $0.045 zone could propel it to $0.055, while a breakdown below $0.036 would amplify the drop. However, there was a previous resistance at $0.05, as analyzed earlier.

Source: USELESS/USDT on TradingView

Altogether, the memecoin was trading inside a key decision area where a breakout in either direction would determine its next trajectory.

Final Summary USELESS rallies more than 17% amid capital inflow from the Top PnL traders, whales, and fresh wallets.  The price of USELESS Coin faced two critical tests at the $0.036 and $0.045 levels.